The Molecular Taxonomy of Primary Prostate Cancer

  title={The Molecular Taxonomy of Primary Prostate Cancer},
  author={Adam Abeshouse and Jaeil Ahn and Rehan Akbani and Adrian Ally and Samirkumar B. Amin and Chris Andry and Matti Annala and Armen G. Aprikian and Joshua Armenia and Arshi Arora and James T. Auman and Miruna Balasundaram and Saianand Balu and Christopher E. Barbieri and Thomas L. Bauer and Christopher C. Benz and Alain Bergeron and Rameen Beroukhim and Mario Berrios and Adrian Bivol and Tom Bodenheimer and L. Peter Boice and Moiz S. Bootwalla and Rodolfo Borges dos Reis and Paul C. Boutros and Jay Bowen and Reanne Bowlby and Jeff Boyd and Anne C. Breggia and Fadi Brimo and Denise Brooks and Bradley M. Broom and Alan H. Bryce and Glenn J. Bubley and Eric J. Burks and Yaron S. N. Butterfield and Michael Button and David Canes and Carlos Gilberto Carlotti and Rebecca Carlsen and Peter R. Carroll and Richard W. Cartun and Brett S Carver and June Maylin Chan and Matthew T. Chang and Yu Chen and Anthony J. Costello and Andrew D. Cherniack and Simone Chevalier and Juok Cho and Andy Chu and Eric Chuah and Sudha Chudamani and Giovanni Domenico Ciriello and Amanda Clarke and Matthew R. Cooperberg and Niall M. Corcoran and Janet E. Cowan and Daniel Crain and Erin E. Curley and Kerstin A. David and John A. Demchok and Francesca Demichelis and Noreen Dhalla and Rajiv Dhir and Alexandre A. Doueik and Bettina F Drake and Heidi Dvinge and N. A. Dyakova and Ina Felau and Martin L Ferguson and Scott R. Frazer and Stephen J. Freedland and Yao Fu and Christopher Aaron Bristow and Jianjiong Gao and Johanna Gardner and Julie M. Gastier-Foster and Nils Gehlenborg and Mark J. Gerken and Mark B. Gerstein and Andrew K. Godwin and Anuradha Gopalan and Markus Graefen and Kiley Graim and Thomas Edward Gribbin and Ranabir Guin and M. K. Gupta and Angela Hadjipanayis and Syed Haider and Lucie Hamel and David Neil Hayes and Julian M. Hess and Katherine A. Hoadley and Andrea E Holbrook and Robert A. Holt and Antonia H. Holway and Christopher M. Hovens and Alan Hoyle and Meijuan Huang and Carolyn Hutter and Michael M Ittmann and Lisa E. Iype and Stuart R. Jefferys and Corbin D. Jones and Steven J. M. Jones and Hartmut Juhl and Andr{\'e} Kahles and Christopher J. Kane and Katayoon Kasaian and Michael Kerger and Ekta Khurana and Jaegil Kim and Robert J. Klein and Raju Kucherlapati and Louis Lacombe and Marc Ladanyi and Phillip H. Lai and Peter W. Laird and Mathieu Latour and Michael S. Lawrence and Kevin R Lau and Tucker W Lebien and Darlene Lee and Semin Lee and Kjong-van Lehmann and Kristen Leraas and Ignaty Leshchiner and Robert A. Leung and John A. Libertino and Tara M. Lichtenberg and W. Marston Linehan and Shiyun Ling and Scott M. Lippman and Jia Liu and Wenbin Liu and Lucas Lochovsky and Christopher J. Logothetis and Laxmi Lolla and Teri A. Longacre and Yiling Lu and Jian-Hua Luo and Yussanne Ma and Harshad S. Mahadeshwar and David W Mallery and Armaz Mariamidze and Marco A. Marra and Michael Mayo and Shannon J. McCall and Ginette McKercher and Shaowu Meng and Anne-Marie Mes-Masson and Mar{\'i}a Merino and Piotr A. Mieczkowski and Gordon B. Mills and Kenna R. Mills Shaw and Sarah Minner and Alireza Moinzadeh and Richard A. Moore and Scott Morris and Carl D. Morrison and Lisle E. Mose and Andrew J. Mungall and Bradley A. Murray and Jerome B. Myers and Rashi Naresh and Joel B. Nelson and Mark Nelson and Peter S. Nelson and Yulia Newton and Michael S. Noble and Houtan Noushmehr and Matti Nykter and Angeliki Pantazi and Michael G Parfenov and Joel S. Parker and Joseph D. Paulauskis and Robert J. Penny and Charles M. Perou and Alain Pich{\'e} and Todd Pihl and Peter A. Pinto and Davide Prandi and Alexei Protopopov and Nilsa C. Ramirez and Arvind U. K. Rao and W. Rathmell and Gunnar R{\"a}tsch and Xiaojia Ren and Victor E. Reuter and Sheila M. Reynolds and Suhn Kyong Rhie and Kimberly M Rieger-Christ and Jeffrey M. Roach and A. Gordon Robertson and Brian D. Robinson and Mark A. Rubin and Fred Saad and Sara Sadeghi and Gordon Saksena and Charles Saller and Andrew L. Salner and Francisco S{\'a}nchez-Vega and Chris Sander and George Sandusky and Guido Sauter and Andrea Sboner and Peter T. Scardino and Eleonora Scarlata and Jacqueline E. Schein and Thorsten Schlomm and Laura S. Schmidt and Nikolaus D. Schultz and Steven E Schumacher and Luciano Neder and Sahil Seth and Alexis Sharp and Candace Shelton and Troy Shelton and Hui Shen and Ronglai Shen and Mark E. Sherman and Margi Sheth and Yan Shi and Juliann Shih and Ilya Shmulevich and Jeffry P. Simko and Ronald Simon and Janae V. Simons and Payal Sipahimalani and Tara J. Skelly and Heidi J. Sofia and Matthew G. Soloway and Xingzhi Song and Andrea Sorcini and Serghei Stepa and Chip Stewart and John H. Stewart and Joshua M. Stuart and Travis B Sullivan and Charlie Sun and Huandong Sun and Angela Tam and Donghui Tan and Jiabin Tang and Roy W. Tarnuzzer and Katherine Tarvin and Barry S. Taylor and Patrick Teebagy and Imelda Tenggara and Bernard Têtu and Ashutosh K. Tewari and Nina Thiessen and Timothy C. Thompson and Leigh B. Thorne and Daniela Tirapelli and Scott A. Tomlins and Felipe Amstalden Trevisan and Patricia Troncoso and Lawrence D. True and Maria Christina Tsourlakis and Svitlana Tyekucheva and Eliezer M. Van Allen and David J. Van Den Berg and Umadevi Veluvolu and Cathy D. Vocke and Yunhu Wan and Qingguo Wang and Wenyi Wang and Zhining Wang and Nils Weinhold and John N. Weinstein and Daniel J. Weisenberger and Matthew D. Wilkerson and Lisa Wise and John S. Witte and Chia-Chin Wu and Junyuan Wu and Ye Wu and Andrew Wei Xu and Shalini Singh Yadav and Liming Yang and Lixing Yang and Christina Yau and Huihui Ye and Peggy Yena and Thomas Zeng and Jean Claude Zenklusen and Hailei Zhang and Jiashan (Julia) Zhang and Wei Zhang and Yi Zhong and Kelsey Zhu and E J Zmuda and Robert K. Bradley and Michelle A. Carmell and Scott L. Carter and Lynda Chin and Kristian Cibulskis and Gad Getz and David I. Heiman and Eric S. Lander and Pei Lin and Massimo Loda and Matthew L Meyerson and Peter J. Park and Jonathan G. Seidman and Carrie Sougnez and Roel G. W. Verhaak and Douglas Voet},

Figures and Tables from this paper

NCOR1 may be a potential biomarker of a novel molecular subtype of prostate cancer

Prostate cancer (PCa) is the most frequently diagnosed male cancer. An earlier study of a cohort of 333 primary prostate carcinomas showed that 74% of these tumors fell into one of seven subtypes of

Molecular subtyping of prostate cancer

The recent advances in the genomic understanding of human prostate cancer, with focus on molecular subclassification are reviewed, including associations with pathologic factors, race, and prognosis, as well as the possibility for future precision therapies.

Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer.

These findings suggest a paradigm in which specific subtypes of PCa follow distinct pathways of progression, at both the molecular and clinical levels, and the interpretation of common clinical parameters may be influenced by the underlying tumor lineage, and potentially influence management decisions.

Harbingers of Aggressive Prostate Cancer: Precision Oncology Case Studies

The results emphasize pathologic and molecular heterogeneity of primary PCa, and suggest that comprehensive IHC-assisted pathology review and genomic analysis are highly concordant in nominating the “index” primary PCA area.

Genomic Profiling of Prostate Cancer: An Updated Review

Emerging evidence for genomic profiling of prostate cancer is reviewed, especially focusing on associations between genomic alteration and clinical outcome, liquid biopsy, and actionable molecular alterations.

The long tail of oncogenic drivers in prostate cancer

A new class of E26 transformation-specific (ETS)-fusion-negative tumors defined by mutations in epigenetic regulators, as well as alterations in pathways not previously implicated in prostate cancer, such as the spliceosome pathway are identified.

Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications

The ensemble of these molecular studies has led to suggest the existence of two main molecular groups of prostate cancers: one characterized by the presence of ERG rearrangements and by the frequent mutations in the E3 ubiquitin ligase adapter SPOP and/or deletion of CDH1, a chromatin remodeling factor.

TP53 alterations of hormone-naïve prostate cancer in the Chinese population

Background Prostate cancer (PCa) shows racial disparity in clinical and genomic characteristics, and Asian patients with PCa often present with more aggressive phenotypes at diagnosis. The ability of



Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis.

The findings reveal that prostate cancers develop via a limited number of alternative preferred genetic pathways and provide a new framework for investigating prostate cancer biology and explain in part the clinical heterogeneity of the disease.

Distinct genomic aberrations associated with ERG rearranged prostate cancer

This study performs genome‐wide profiling of 49 primary prostate cancers and identifies 20 recurrent chromosomal copy number aberrations, mainly occurring as genomic losses, and demonstrates that high‐resolution tiling arrays can be used to pin‐point breakpoints leading to fusion events.

The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer

The mutational landscape of a heavily treated metastatic cancer is described, novel mechanisms of AR signalling deregulated in prostate cancer are identified, and candidates for future study are prioritize.

Comprehensive molecular profiling of lung adenocarcinoma

High rates of somatic mutation were seen, including RIT1 activating mutations and newly described loss-of-function MGA mutations which are mutually exclusive with focal MYC amplification, and MAPK and PI(3)K pathway activity was explained by known mutations in only a fraction of cases, suggesting additional, unexplained mechanisms of pathway activation.

The genomic complexity of primary human prostate cancer

Genomic rearrangements may arise from transcriptional or chromatin aberrancies and engage prostate tumorigenic mechanisms, suggesting a link between chromatin or transcriptional regulation and the genesis of genomic aberrations.

Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors.

Integrative genomic profiling of human prostate cancer.

Spatial genomic heterogeneity within localized, multifocal prostate cancer

A new recurrent amplification of MYCL is identified and validated, which is associated with TP53 deletion and unique profiles of DNA damage and transcriptional dysregulation, and this data represents the first systematic relation of intraprostatic genomic heterogeneity to predicted clinical outcome.

IDH mutation status in prostate cancer

IDH1/2 mutations in localized prostate cancer (PCa), which has significant heterogeneity in genomic stability, tumor metabolism and clinical outcome, are determined and the value of documenting mutant IDH1 and IDH2 enzymes as targets for individualized and novel cancer therapies is highlighted.